Tripeptidyl Peptidase II Mediates Levels of Nuclear Phosphorylated ERK1 and ERK2

Anne Wiemhoefer, Anita Stargardt, Wouter A. van der Linden, Maria C. Renner, Ronald E. van Kesteren, Jan Stap, Marcel A. Raspe, Birgitta Tomkinson, Helmut W. Kessels, Huib Ovaa, Herman S. Overkleeft, Bogdan Florea, Eric A. Reits

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)


Tripeptidyl peptidase II (TPP2) is a serine peptidase involved in various biological processes, including antigen processing, cell growth, DNA repair, and neuropeptide mediated signaling. The underlying mechanisms of how a peptidase can influence this multitude of processes still remain unknown. We identified rapid proteomic changes in neuroblastoma cells following selective TPP2 inhibition using the known reversible inhibitor butabindide, as well as a new, more potent, and irreversible peptide phosphonate inhibitor. Our data show that TPP2 inhibition indirectly but rapidly decreases the levels of active, di-phosphorylated extracellular signal-regulated kinase 1 (ERK1) and ERK2 in the nucleus, thereby down-regulating signal transduction downstream of growth factors and mitogenic stimuli. We conclude that TPP2 mediates many important cellular functions by controlling ERK1 and ERK2 phosphorylation. For instance, we show that TPP2 inhibition of neurons in the hippocampus leads to an excessive strengthening of synapses, indicating that TPP2 activity is crucial for normal brain function
Original languageEnglish
Pages (from-to)2177-2193
JournalMolecular & cellular proteomics
Issue number8
Publication statusPublished - 2015

Cite this